自拍亚洲日本少妇,日韩精品久久无码二区 ,4hu四虎永久在线影院97年小娇妻

Technology platforms

Excellent platform for production and optimization of polypeptide and protein drugs

QLFold

Details

QLLong

Details

QLFusion

Details

QLOral

Details

QLFold

QLLong

QLFusion

QLOral

Diversified recombinant proteins meet biopharmaceutical needs

Currently, there are 10 understudied recombinant protein innovative drugs
and biosimilar varieties in QL Biopharm's pipelines

Delve deep into the field of metabolism and become a leader in the industry
Excellent platform for production and optimization of polypeptide and protein drugs

Details

About Us

Delve deep into the field of metabolism and become a leader in the industry

Founded in September 2018, QL Biopharm specializes in the production of recombinant protein drugs using Escherichia coli. The company is committed to developing innovative biological drugs for the treatment of chronic metabolic diseases, such as diabetes, obesity, and nonalcoholic steatohepatitis, aiming to improve the quality of life for people around the world. Currently, there are 10 understudied recombinant protein innovative drugs and biosimilar varieties in QL Biopharm’s pipelines. By the end of 2022, two of our independently developed, world-leading innovative drugs and one domestic alternative international major variety generic drug had entered the clinical trial stage.

2018
Incorporated in 2018
10
10 pipelines
4
4 independent innovation
technology platforms

Details

News Center

Build a bright future together with QL Biopharm

QL Pharmaceuticals Receives Commercial Manufacturing Approval for ZT001 Company News2025-12-29

2025-12-29 QL Pharmaceuticals Receives Commercial Manufacturing Approval for ZT001

TAIZHOU, China, December 28, 2025 - On December 26, 2025, Zhitai Pharmaceuticals (Taizhou) Co, Ltd (QL Pharmaceuticals), a wholly-owned subsidiary of Beijing QL Biopharmaceutical Co, Ltd (QL Biopharm or company), received approval by China's National Medical Products Administration (NMPA) to manufacture commercial material of ZT001, a semaglutide biosimilar. This approval marks a crucial milestone for the company in the field of commercial drug manufacturing for ZT001 and potentially additional programs in QL Biopharm's pipeline.

Details

QL Biopharm Doses First Subject in Phase 2 Study with ZT006, an Oral GLP-1 RA Being Evaluated for the Treatment of Obesity Company News2025-12-18

2025-12-18 QL Biopharm Doses First Subject in Phase 2 Study with ZT006, an Oral GLP-1 RA Being Evaluated for the Treatment of Obesity

BEIJING, China, December 12, 2025 - Beijing QL Biopharmaceutical Co, Ltd (QL Biopharm) dosed its first patient with ZT006, its novel oral GLP-1 receptor agonist (GLP-1 RA), ZT006, in a Phase 2 obesity study.

Details

QL Biopharm Doses First Subject with ZT003, a GLP-1/FGF21 Dual Agonist Being Evaluated for the Treatment of MASH Company News2025-11-25

2025-11-25 QL Biopharm Doses First Subject with ZT003, a GLP-1/FGF21 Dual Agonist Being Evaluated for the Treatment of MASH

BEIJING, China, November 23, 2025 - Beijing QL Biopharmaceutical Co, Ltd (QL Biopharm) dosed its first patient in Australia with ZT003, its innovative GLP-1/FGF21 fusion peptide and dual agonist investigational new medicine.

Details

QL Biopharm reports Phase 2 results of a monthly dose study evaluating zovaglutide, a novel, extended half-life GLP-1 receptor agonist at EASD 2025 Company News2025-09-17

2025-09-17 QL Biopharm reports Phase 2 results of a monthly dose study evaluating zovaglutide, a novel, extended half-life GLP-1 receptor agonist at EASD 2025

BEIJING, China, September 17, 2025 – Beijing QL Biopharmaceutical Co., Ltd. (hereafter "QL Biopharm" or the "company") announced today at the European Association for the Study of Diabetes (EASD) annual meeting that its novel experimental therapy in the management of obesity met both its primary and secondary endpoints in a randomized, double-blind, placebo-controlled Phase 2 trial.

Details

QL Biopharm's GLP-1/FGF21 Dual Agonist ZT003 Obtains FDA Approval for New Drug Clinical Trial Company News2025-06-30

2025-06-30 QL Biopharm's GLP-1/FGF21 Dual Agonist ZT003 Obtains FDA Approval for New Drug Clinical Trial

On June 27, 2025, ZT003 Injection, an innovative GLP-1/FGF21 dual agonist independently developed by Beijing QL Biopharmaceutical, was officially approved for clinical trial by the U.S. Food and Drug Administration (FDA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). ZT003 is on track to launch phase I clinical trials abroad, marking a significant step forward in QL Biopharm's international strategy for innovative drugs.

Details

QL Biopharm Holds Phase 2 Clinical Trial Investigators Meeting for ZT006, its Once-Daily Oral GLP-1RA Peptide Company News2026-01-06

2026-01-06 QL Biopharm Holds Phase 2 Clinical Trial Investigators Meeting for ZT006, its Once-Daily Oral GLP-1RA Peptide

BEIJING, China, January 5, 2026 - On December 26, 2025, Beijing QL Biopharmaceutical Co, Ltd (QL Biopharm), successfully held an investigators meeting in Beijing for its Phase 2 clinical trial entitled, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Different Doses of ZT006 Tablets in Overweight or Obese Participants.”

Details